A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

• Drug: PF-03882845
  
  3 mg tablet once daily
• Drug: PF-03882845
  
  up to 10 mg tablet once daily
• Drug: PF-03882845
  
  up to 30 mg once daily
• Drug: Spironolactone
  
  spironolactone 25 mg once daily
• Other: placebo
  
  placebo once daily

• Experimental: PF03882845
  
  Interventions:
  

  • Drug: PF-03882845
  • Drug: PF-03882845
  • Drug: PF-03882845
• Active Comparator: Spironolactone
  
  25 mg once daily
  Intervention: Drug: Spironolactone
• Placebo Comparator: Placebo
  
  Placebo once daily
  Intervention: Other: placebo

Inclusion Criteria:

• Males and/or Females between 18-65 years, inclusive.
• Body mass index of 18.5 to 45.4 kg/m2 at screening, inclusive. body weight equals or greater than 110 lb.
• Have type 2 diabetes mellitus.
• On stable dose of anti-diabetic and anti-hypertensive medication prior to screening.

Exclusion Criteria:

• Recent evidence or medical history of unstable concurrent disease.
• Cardiovascular event within 3 months prior to screening.
• History of renal transplant.
• History of hospitalization for acute kidney injury or acute kidney dialysis within 6 months prior to screening.